FDA Panel Votes Against Arena's Diet Drug

Another diet drug, Arena Pharmaceuticals's Iorcaserin, appears to be in danger after a U.S. Food and Drug Administration advisory panel voted to reject it Thursday.

Vivus Hammered After FDA Panel's 'No' Vote

Pharmaceutical company Vivus is getting hammered in premarket trading, sinking more than 50% to around $5.32 in the wake of Thursday's vote by an FDA advisory panel against approving its weight-loss drug, Qnexa, based on safety concerns.